
# Clinical Protocol - STUDY002

## Title
A Randomized, Double-Blind, Placebo-Controlled Study of Drug A in Indication

## Sponsor
Pharma Corporation

## Phase
Phase II/III

## Objectives
### Primary
To evaluate the efficacy and safety of Drug A compared to placebo.

### Secondary
- To assess dose-response relationship
- To evaluate quality of life
- To assess long-term safety

## Study Design
- Type: Interventional
- Assignment: Randomized
- Masking: Double-blind
- Control: Placebo
- Allocation: Randomized

## Population
### Inclusion Criteria
1. Age 18-85 years
2. Diagnosis of indication
3. Able to provide informed consent
4. Willing to comply with study procedures

### Exclusion Criteria
1. Prior exposure to study drug
2. Significant comorbidities
3. Pregnant or breastfeeding
4. Participation in another trial

## Interventions
### Drug A
- Dose: 100mg daily
- Route: Oral
- Duration: 12 weeks

### Placebo
- Matching placebo
- Same schedule as active drug

## Assessments
### Efficacy
- Primary endpoint assessed at Week 12
- Secondary endpoints at Weeks 4, 8, 12
- Follow-up at Week 16

### Safety
- Adverse events throughout study
- Laboratory parameters at each visit
- Vital signs at each visit
- ECG at baseline and Week 12

## Sample Size
- Total subjects: 50
- Placebo: 16
- Drug A: 16
- Drug B: 16

## Statistical Considerations
### Analysis Sets
- Intent-to-Treat (ITT)
- Per Protocol (PP)
- Safety

### Hypothesis Testing
- Primary hypothesis: H0: No difference vs H1: Difference exists
- Two-sided alpha = 0.05
- Power = 80%

## Ethics
- IRB/IEC approval required
- GCP compliance
- Informed consent mandatory
- Subject confidentiality protected

## References
1. ICH E6(R2) Good Clinical Practice
2. ICH E9 Statistical Principles
3. CDISC Standards
